As mentioned earlier in this issue of TreatmentUpdate, in Canada and other high-income countries the use of potent anti-HIV therapy (commonly called ART or HAART) during pregnancy along with other steps can greatly reduce the risk of mother-to-child transmission of HIV.
Protease inhibitors are a commonly prescribed class of anti-HIV drugs for pregnant women in high-income countries. Examples of protease inhibitors in common use today include the following:
Researchers in Toronto and elsewhere in Canada have found that "the benefits of ART far outweigh the potential adverse effects" for both the mother and the fetus. However, in recent years, as treatment guidelines in high-income countries shift toward encouraging all HIV-positive people, regardless of CD4+ count, to initiate ART, and new drugs have become available, more research is needed to help doctors better understand the safety of ART during pregnancy.
Some studies have found an increased risk for the following problems in HIV-positive pregnancies:
The cause of these problems is not clear.
Researchers in Toronto have been investigating the potential impact of protease inhibitors on pregnancy. In a series of complex experiments, researchers studied the impact of ART on cells, mice and pregnant women. Their findings suggest that a particular component of ART -- the class of anti-HIV drugs called protease inhibitors -- reduces levels of the hormone progesterone. This hormone is important for the growth and survival of the fetus. The researchers are planning a pilot study of a progesterone cream with pregnant HIV-positive women who use protease inhibitors.
In experiments in the lab with cells that can develop and form the placenta, researchers studied the impact of anti-HIV drugs, either singly or in combinations commonly used in pregnancy. The researchers tested three main classes of anti-HIV drugs as follows:
The three main protease inhibitors -- atazanavir, darunavir and lopinavir -- are generally taken with a small dose of another protease inhibitor, ritonavir. The purpose of the small dose of ritonavir is to raise the concentration of the main protease inhibitor in the blood and keep it elevated for about 24 hours. In this way, many regimens containing protease inhibitors can be taken just once daily. Ritonavir has this effect in a large part because it impairs the activity of enzymes in the intestine and liver that can break down protease inhibitors. It also impairs the activity of tiny pumps inside of cells that attempt to flush foreign substances out of a cell. Ritonavir and other drugs that have a similar effect are commonly called boosters.
As protease inhibitors are generally used with a booster, researchers tested combinations of protease inhibitors with low-dose ritonavir.
The researchers used cells that develop into the placenta. They found that, in general, exposure to protease inhibitors (singly) reduced the cells' production of progesterone. The strongest effect was seen with exposure to ritonavir. However, atazanavir and lopinavir also reduced progesterone production. Exposure to darunavir did not reduce progesterone production.
Similar effects were seen when protease inhibitors were used in combination with ritonavir. Neither nukes nor non-nukes affected progesterone levels.
Researchers gave pregnant mice doses of protease inhibitors that resulted in drug concentrations similar to those seen in pregnant women who use such drugs. The researchers found that protease inhibitor-based regimens significantly reduced progesterone concentrations in mice. Furthermore, by reducing the level of progesterone in the pregnant mice, protease inhibitors indirectly affected fetal health by reducing the chances of survival. A mouse's body can absorb a dead fetus in a process called resorption. Among the fetuses that did not undergo resorption, most did not achieve a normal weight while in the wombs of pregnant mice.
It is important to bear in mind that mice in this experiment received very high concentrations (for mice) of protease inhibitors. As such, it should not be surprising that they experienced adverse reactions, both biochemically and physically. However, such concentrations of protease inhibitors are within the normal and safe range for humans and there have not been any reports of fetal resorption in HIV-positive pregnant women treated with protease inhibitors.
In contrast, pregnant mice given a combination of ATZ + 3TC did not develop problems with progesterone and their fetuses were of normal weight. However, the survival of the fetuses was affected as resorption still occurred for some reason.
Researchers gave some pregnant mice on protease inhibitors supplements of progesterone. As a result, the weights of their fetuses increased but did not reach the normal range. Furthermore, some fetuses continued to die and undergo resorption by the mother.
|What Did You Expect While You Were Expecting?|
|HIV/AIDS Resource Center for Women|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.